Company* (Country; Symbol) |
Product |
Description |
Indication |
Status (Date) |
| ||||
AUTOIMMUNE | ||||
Amgen Inc. (AMGN) |
Enbrel (FDA-approved) |
Etanercept; anti-TNF-alpha antibody |
Ankylosing spondylitis |
Partner Wyeth gained approval in Europe to sell the drug for those with severe, active disease (1/20) |
|
||||
Antisense Therapeutics Ltd. (Australia; ASX:ANP) |
ATL1102 |
Second-generation antisense drug |
Multiple sclerosis |
Preliminary Phase I data were positive in terms of safety and pharmacokinetics (1/30) |
|
||||
CANCER | ||||
Bioenvision Inc. (AMEX:BIV) |
Clofarabine |
Next-generation purine nucleoside antimetabolite |
Acute myelogenous leukemia |
Phase II trial in the UK began involving older adults not suitable for intensive chemotherapy (1/14) |
|
||||
Biogen Idec Inc. (BIIB) |
Zevalin (FDA-approved) |
Ibritumomab tiuxetan; monoclonal antibody targeting CD20 combined with radioisotope |
Non-Hodgkin's lymphoma |
The product was approved in Europe for treating adults with CD20+ follicular B-cell NHL who are refractory to Rituxan; it will be sold there by Schering AG (1/22) |
|
||||
MediGene AG (Germany; FSE:MDG) |
Eligard 22.5 mg |
Leuprolide acetate for injectable suspension |
Prostate cancer |
German authorities approved the product, which was developed by Atrix Laboratories Inc. (1/26) |
|
||||
Millennium Pharmaceuticals Inc. (MLNM) |
Velcade (FDA-approved) |
Bortezomib; proteasome inhibitor |
Multiple myeloma |
European regulators recommended approval under exceptional circumstances for treating patients whose disease has progressed under prior treatments (1/22) |
|
||||
Munich Biotech AG* (Germany) |
MBT-0206 |
Anti-neovascular agent containing paclitaxel and a lipid-based carrier |
Metastatic breast and pancreatic cancer |
Company started Phase II trial in each indication; the pancreatic trial is for first-line treatment in combination with gemcitabine in 70 patients; the breast cancer trial is a second- or third-line monotherapy trial in 60 patients (1/16) |
|
||||
Oxford BioMedica plc (UK; LSE:OXB) |
TroVax |
Vaccine that delivers an antigen (5T4) using a pox virus vector |
Colorectal cancer |
Company got approval for Phase II study in UK of 20 patients who are undergoing surgery for resectable liver metastases (1/16) |
|
||||
Wilex AG* (Germany) |
WX-UK1 |
Synthetic small-molecule inhibitor of serine proteases |
Head and neck cancers |
Company started a Phase Ib trial in Germany to assess safety, toler- ability and biological activity as a monotherapy (1/14) |
|
||||
CARDIOVASCULAR | ||||
GTC Biotherapeutics Inc. (GTCB) |
ATryn |
Recombinant human antithrombin product produced in the milk of goats |
Hereditary antithrombin deficiency |
GTC submitted an approval application in Europe; the indication in HD patients is prophylaxis of deep-vein thrombosis and thromboembolism in clinical-risk situations (1/26) |
|
||||
Jerini AG* (Germany) |
Icatibant (JE049) |
Bradykinin-2 receptor antagonist |
Hereditary angioedema |
Company said angioedema symptoms resolved rapidly in all eight patients in the Phase II European trial (1/13) |
|
||||
United Therapeutics Corp.(UTHR) |
Remodulin (FDA-approved) |
Treprostinil sodium injection |
Pulmonary arterial hypertension |
French officials issued an action letter requesting additional information before product could be approved (1/6) |
|
||||
CENTRAL NERVOUS SYSTEM | ||||
Labopharm Inc. (Canada; TSE:DDS) |
-- |
Once-daily formulation of the analgesic tramadol |
Pain |
French authorities sent a letter asking for clarification on the approval request there (1/28) |
|
||||
NiCox SA (France; Nouveau Marche: NICOX) |
NCX 4016 |
Nitric oxide-donating derivative of aspirin |
Peripheral arterial obstructive disease |
NiCox said Phase IIa trial in Italy reached its primary efficacy end- point of reversing endothelium dysfunction induced by physical exercise (1/8) |
|
||||
Pain Therapeutics Inc. (PTIE) |
Remoxy |
Capsule formulation of oxycodone, designed to be abuse-resistant |
Pain |
Company started a Phase I trial to assess safety and pharmacokinetics against placebo and active drug in healthy volunteers in the UK (1/15) |
|
||||
DIABETES | ||||
Amylin Pharmaceuticals Inc. (AMLN) |
Symlin |
Pramlintide acetate; an analogue of human amylin |
Diabetes |
Swiss officials said they would not approve the product based on data received; Amylin withdrew its approval application (1/7) |
|
||||
INFECTION | ||||
Avant Immunotherapeutics Inc. (AVAN) |
CholeraGarde |
Single-dose oral vaccine |
Cholera |
Avant released positive preliminary results from Phase II trial in 70 adults in Bangladesh; vaccine was well tolerated and more than 70% of adults had a favorable immune response (1/20) |
|
||||
Sinovac Biotech Inc.* (China; OTC BB:SNVBF) |
-- |
Vaccine for severe acute respiratory syndrome |
SARS |
Company gained approval to initiate clinical trials in 30 subjects in China (1/20) |
|
||||
Stratus Research Labs Inc.* |
A-221-HIV |
Drug designed to target HIV-infected cells and put them in a nondividing state |
HIV |
Company said it was about to begin human trials in Latin Amer- ica (1/30) |
|
||||
VaxGen Inc. (VXGN) |
rPA102 |
Recombinantly produced anthrax vaccine |
Anthrax |
The FDA granted fast-track status to the product, for which VaxGen has government contracts to develop (1/21) |
|
||||
MISCELLANEOUS | ||||
Aastrom Biosciences Inc. (ASTM) |
Tissue Repair Cell |
Stem and progenitor cells produced from samples of a patient's own bone marrow |
Leg fractures |
Company began trial in Germany in combination with a synthetic bone graft matrix in 10 patients with serious fractures (1/22) |
|
||||
Biolipox AB* (Sweden) and NiCox SA (France; Novuea Marche: NICOX) |
NCX 1510 |
Agent delivered via nasal spray |
Allergic rhinitis |
Biolipox started a Phase IIa trial in 36 patients in Sweden to look at efficacy in an out-of-season allergen-provocation study (1/21) |
|
||||
Enhance Biotech Inc. (OTC BB:EBOI) |
LI 301 |
Existing undisclosed drug |
Premature ejaculation |
Company said Phase IIa trial in Europe showed positive effect vs. placebo (1/27) |
|
||||
Genzyme Corp. (GENZ) |
Fabrazyme (agalsidase beta) |
Enzyme replacement therapy |
Fabry's disease |
Genzyme received approval to market the product in Japan as soon as officials there establish a price (1/29) |
|
||||
Proskelia SAS* (France) |
PSK 3471 |
Selective estrogen receptor modulator |
Osteoporosis |
Company started a Phase IIa trial (1/28)** |
|
||||
| ||||
Notes: | ||||
* Privately held. | ||||
** Denotes the date item ran in BioWorld International. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. |